Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Sjoquist KM, Dobrovic A, Robledo KP, Nesic K, Baron-Hay S, Ananda S, McCarthy N, Goh J, Steer C, Murray N, Yip S, Mileshkin LR, Fink JL, Chang G, Bailey L, Lee Y, Zebic DS, Kariyawasam UGIU, Shield-Artin K, Jarratt A, Bedő J, Papenfuss AT, Kondrashova O, Wakefield MJ, Vandenberg CJ, Stockler MR, Scott CL, Waring PM.

Open source

DOI: 10.1038/s41416-026-03535-6
Published: 2026-07-08
Container: Br J Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41416-026-03535-6,
  title = {Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.},
  author = {Sjoquist KM and  Dobrovic A and  Robledo KP and  Nesic K and  Baron-Hay S and  Ananda S and  McCarthy N and  Goh J and  Steer C and  Murray N and  Yip S and  Mileshkin LR and  Fink JL and  Chang G and  Bailey L and  Lee Y and  Zebic DS and  Kariyawasam UGIU and  Shield-Artin K and  Jarratt A and  Bedő J and  Papenfuss AT and  Kondrashova O and  Wakefield MJ and  Vandenberg CJ and  Stockler MR and  Scott CL and  Waring PM.},
  year = {2026},
  journal = {Br J Cancer},
  doi = {10.1038/s41416-026-03535-6},
  url = {https://doi.org/10.1038/s41416-026-03535-6}
}

RIS

TY  - JOUR
TI  - Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.
AU  - Sjoquist KM
AU  -  Dobrovic A
AU  -  Robledo KP
AU  -  Nesic K
AU  -  Baron-Hay S
AU  -  Ananda S
AU  -  McCarthy N
AU  -  Goh J
AU  -  Steer C
AU  -  Murray N
AU  -  Yip S
AU  -  Mileshkin LR
AU  -  Fink JL
AU  -  Chang G
AU  -  Bailey L
AU  -  Lee Y
AU  -  Zebic DS
AU  -  Kariyawasam UGIU
AU  -  Shield-Artin K
AU  -  Jarratt A
AU  -  Bedő J
AU  -  Papenfuss AT
AU  -  Kondrashova O
AU  -  Wakefield MJ
AU  -  Vandenberg CJ
AU  -  Stockler MR
AU  -  Scott CL
AU  -  Waring PM.
PY  - 2026
JO  - Br J Cancer
DO  - 10.1038/s41416-026-03535-6
UR  - https://doi.org/10.1038/s41416-026-03535-6
ER  -

APA

KM, S., A, D., KP, R., K, N., S, B., S, A., N, M., J, G., C, S., N, M., S, Y., LR, M., JL, F., G, C., L, B., Y, L., DS, Z., UGIU, K., K, S., A, J., J, B., AT, P., O, K., MJ, W., CJ, V., MR, S., CL, S., & PM., W. (2026). Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.. Br J Cancer. https://doi.org/10.1038/s41416-026-03535-6

Source records

europe-pmc · retrieved 2026-09-26T15:00:20.665Z